82|10000|Public
5|$|Toxicology testing became {{important}} in the 20th century. In the 19th century, laws regulating drugs were more relaxed. For example, in the U.S., the government could only ban a drug after a company had been prosecuted for selling products that harmed customers. However, {{in response to the}} Elixir Sulfanilamide disaster of 1937 in which the eponymous drug killed more than 100 users, the U.S. congress passed laws that required safety <b>testing</b> <b>of</b> <b>drugs</b> on animals before they could be marketed. Other countries enacted similar legislation. In the 1960s, in reaction to the Thalidomide tragedy, further laws were passed requiring safety testing on pregnant animals before a drug can be sold.|$|E
25|$|The use of {{non-human}} primates in the EU {{is regulated}} under the Directive 2010/63/EU. The directive took effect on January 1, 2013. The directive permits {{the use of}} non-human primates if no other alternative methods are available. Testing on non-human primates is permitted for basic and applied research, quality and safety <b>testing</b> <b>of</b> <b>drugs,</b> food and other products and research aimed on {{the preservation of the}} species. The use of great apes is generally not permitted, unless it is believed that the actions are essential to preserve the species or in relation to an unexpected outbreak of a life-threatening or debilitating clinical condition in human beings. The directive stresses the use of the 3R principle (replacement, refinement, reduction) and animal welfare when conducting animal testing on non-human primates.|$|E
2500|$|Avicenna (Ibn Sina) is {{considered}} the father of modern medicine, for his introduction of experimental medicine and clinical trials, the experimental use and <b>testing</b> <b>of</b> <b>drugs,</b> and a precise guide for practical experimentation {{in the process of}} discovering and proving the effectiveness of medical substances, in his medical encyclopedia, The Canon of Medicine (11th century), which was the first book dealing with experimental medicine. It laid out the following rules and principles for testing the effectiveness of new drugs or medications, which still form the basis of modern clinical trials: ...|$|E
50|$|Some {{fruit juices}} and fruits can {{interact}} with numerous drugs, {{in many cases}} causing adverse effects. The effect was first discovered by accident, when a <b>test</b> <b>of</b> <b>drug</b> interactions with alcohol used grapefruit juice to hide {{the taste of the}} ethanol.|$|R
40|$|P. 58 Alcohol - {{tables and}} figures •	Lifestyle alcohol consumption: How {{often do you}} drink alcohol •	Driven a motor vehicle after {{consuming}} any alcohol (Past 12 months) •	How much alcohol can you consume and be safe to drive? •	How much alcohol can you consume and remain under the legal limit •	Medication & drugs and driving •	Support for roadside <b>testing</b> <b>of</b> <b>drug</b> us...|$|R
50|$|Kligman's {{prisoner}} {{testing for}} the government {{was not limited to}} dermatology, extending even to the <b>testing</b> <b>of</b> psychoactive <b>drugs</b> for the Department of Defense.|$|R
2500|$|Personalized care {{solutions}} {{are a key}} aim of the VPH, with new modelling environments for predictive, individualized healthcare to result in better patient safety and drug efficacy. It is anticipated that the VPH {{could also result in}} healthcare improvement through greater understanding of pathophysiological processes. The use of biomedical data from a patient to simulate potential treatments and outcomes could prevent the patient from experiencing unnecessary or ineffective treatments. [...] The use of in silico (by computer simulation) modelling and <b>testing</b> <b>of</b> <b>drugs</b> could also reduce the need for experiments on animals.|$|E
2500|$|Eighty-two {{percent of}} primate {{procedures}} in the UK in 2006 were in applied studies, which the Home Office defines as research conducted {{for the purpose of}} developing or testing commercial products. Toxicology testing is the largest use, which includes legislatively required <b>testing</b> <b>of</b> <b>drugs.</b> The second largest category of research using primates is [...] "protection of man, animals, or environment", accounting for 8.9% of all procedures in 2006. The third largest category is [...] "fundamental biological research,", accounting for 4.9% of all UK primate procedures in 2006. This includes neuroscientific study of the visual system, cognition, and diseases such as Parkinson's, involving techniques such as inserting electrodes to record from or stimulate the brain, and temporary or permanent inactivation of areas of tissue.|$|E
50|$|The FDA Animal Efficacy Rule (also {{known as}} Animal Rule) applies to {{development}} and <b>testing</b> <b>of</b> <b>drugs</b> and biologicals {{to reduce or}} prevent serious/life-threatening conditions caused by exposure to lethal or permanently disabling toxic agents (chemical, biological, radiological, or nuclear substances), where human efficacy trials are not feasible or ethical. The animal efficacy rule was finalized by the FDA and authorized by the United States Congress in 2002, following the September 11 attacks and concerns regarding bioterrorism.|$|E
40|$|In present work, {{one of the}} ornamentals and medicinally less known plant Cassia javanica {{has been}} {{explored}} for hypoglycemic potential. It aimed to check the hypoglycemic effect of C. javanica leaves on normal and streptozotocin (STZ) -induced diabetic rats by acute and sub-acute studies. Prior to the hypoglycemic study, acute oral toxicity <b>testing</b> <b>of</b> <b>drug</b> was performed. Later, the effects of single and multiple doses <b>of</b> <b>test</b> <b>drug</b> were studied using various parameters. Dried powdered leaf material {{was used as an}} oral drug. The preliminary phytochemistry <b>of</b> <b>drug</b> was done by standard qualitative tests. Diabetes was induced in rats by single intraperitoneal injection of STZ. Single and multiple doses <b>of</b> <b>test</b> <b>drug</b> (0. 5 g/kg body weight/day) were given to normal and diabetic rats. The parameters studied were blood glucose, serum cholesterol, serum triglycerides, and serum proteins. The results <b>of</b> <b>test</b> <b>drug</b> were compared with standard hypoglycemic drug-glibenclamide (0. 01 g/kg/day). Statistical analysis was done by ‘Student's ‘t’ test’ and one way ANOVA test. In preliminary phytochemistry, antidiabetic compounds were detected. Unlike acute, subacute treatment <b>of</b> <b>test</b> <b>drug</b> showed highly significant reduction (37. 62 %) in blood glucose level of diabetic rats in ten days. This effect was considerably good in comparison with standard drug (63. 51 %). The test drug and standard drug exhibited insignificant change in the abnormal levels of serum metabolites of diabetic rats. Preclinically, C. javanica was proved to be effective hypoglycemic agent...|$|R
5000|$|... 1 Positive <b>drug</b> <b>test</b> <b>of</b> Kapachinskaya2 Positive <b>drug</b> <b>test</b> <b>of</b> Yefremova ...|$|R
40|$|The Academy of Pharmaceutical Sciences (APSGB) {{is delighted}} {{to partner with}} the British Journal of Pharmacy to publish key abstracts of posters {{presented}} at this year’s APS PharmSci Conference held at the University of Hertfordshire 5 th to 7 th September 2017. The Conference is the premier pharmaceutical sciences event in the UK focussing on ‘The Science of Medicines’ and covers all aspects related to the discovery, development, production and <b>testing</b> <b>of</b> <b>drug</b> products...|$|R
50|$|In 2009, Dr. Reddy’s Laboratories requested, and Celgene {{refused to}} provide, a samples of Celgene's anticancer drug THALOMID® (thalidomide). Dr. Reddy's Laboratories sought the {{material}} for bioequivalency studies required to bring its own, generic, version of thalidomide to market. In {{response to the}} refusal, Dr. Reddy's Laboratories filed a Citizen's Petition with the FDA asking the Agency to adopt procedures that would ensure generic applicants {{the right to buy}} sufficient samples to perform bioequivalence <b>testing</b> <b>of</b> <b>drugs</b> that were subject to REMS distribution restrictions.|$|E
5000|$|Avicenna (Ibn Sina) is {{considered}} the father of modern medicine, for his introduction of experimental medicine and clinical trials, the experimental use and <b>testing</b> <b>of</b> <b>drugs,</b> and a precise guide for practical experimentation {{in the process of}} discovering and proving the effectiveness of medical substances, in his medical encyclopedia, The Canon of Medicine (11th century), which was the first book dealing with experimental medicine. It laid out the following rules and principles for testing the effectiveness of new drugs or medications, which still form the basis of modern clinical trials: ...|$|E
5000|$|In 2014, the American Academy of Pediatrics {{released}} a statement regarding off-label use of pharmaceuticals in children. The article recommends to pediatricians that [...] "Off-label use is neither incorrect nor investigational if based on sound scientific evidence, expert medical judgment, or published literature" [...] and that [...] "Evidence, not label indication, remains the gold standard from which practitioners should draw when making therapeutic decisions for their patients." [...] The statement further advocates additional support and additional incentives for clinical <b>testing</b> <b>of</b> <b>drugs</b> in children, and publication of all results irrespective of positive outcome.|$|E
5000|$|Materials <b>testing,</b> {{for example}} <b>of</b> <b>drug</b> type, paper type, ink type ...|$|R
40|$|<b>Testing</b> <b>of</b> new <b>drugs</b> in small-cell {{lung cancer}} is {{definitely}} {{necessary for the}} development of agents that might be effective against this tumor. However, testing such drugs in previously untreated patients with a good performance status (PS) may give rise to ethical problems. When previously treated patients are used in testing, potentially effective agents could well elude discovery. Patients who are not eligible for "standard" combination chemotherapy, e. g. untreated patients with a poor PS, may be suitable for <b>testing</b> <b>of</b> new <b>drugs.</b> To evaluate the potential usefulness of such patients in the <b>testing</b> <b>of</b> new agents, we evaluated an effective drug (etoposide) at a relatively non-toxic dose in a group of 14 patients with a PS of 4 (WHO). Oral etoposide resulted in a response in only 3 cases, whereas 5 subjects died of therapy-related toxicity. We conclude that previously untreated patients with a poor PS are not suitable candidates for the <b>testing</b> <b>of</b> new <b>drugs...</b>|$|R
5000|$|Materials {{mimicking}} animal mucosal tissues to be {{used for}} <b>testing</b> mucoadhesive properties <b>of</b> <b>drug</b> delivery systems ...|$|R
5000|$|Personalized care {{solutions}} {{are a key}} aim of the VPH, with new modelling environments for predictive, individualized healthcare to result in better patient safety and drug efficacy. It is anticipated that the VPH {{could also result in}} healthcare improvement through greater understanding of pathophysiological processes. The use of biomedical data from a patient to simulate potential treatments and outcomes could prevent the patient from experiencing unnecessary or ineffective treatments. [...] The use of in silico (by computer simulation) modelling and <b>testing</b> <b>of</b> <b>drugs</b> could also reduce the need for experiments on animals.|$|E
50|$|The FDA {{has had the}} {{responsibility}} of reviewing drugs since {{the passage of the}} 1906 Pure Food and Drugs Act. The 1938 Federal Food, Drug and Cosmetic Act required all new drugs to be tested before marketing by submitting the original form of the new drug application. Within the first year, the FDA's Drug Division, the predecessor to CDER, received over 1200 applications. The Drug Amendments of 1962 required manufacturers to prove to the FDA that the drug in question was both safe and effective. In 1966, the division was reorganized to create the Office of New Drugs, which was responsible for reviewing new drug applications and clinical <b>testing</b> <b>of</b> <b>drugs.</b>|$|E
50|$|Toxicology testing became {{important}} in the 20th century. In the 19th century, laws regulating drugs were more relaxed. For example, in the U.S., the government could only ban a drug after a company had been prosecuted for selling products that harmed customers. However, {{in response to the}} Elixir Sulfanilamide disaster of 1937 in which the eponymous drug killed more than 100 users, the U.S. congress passed laws that required safety <b>testing</b> <b>of</b> <b>drugs</b> on animals before they could be marketed. Other countries enacted similar legislation. In the 1960s, in reaction to the Thalidomide tragedy, further laws were passed requiring safety testing on pregnant animals before a drug can be sold.|$|E
40|$|Tests were {{performed}} with 104 anaerobic microorganisms {{to evaluate the}} thioglycolate disk elution technique {{for the detection of}} resistance to cefoperazone and cefoperazone-sulbactam. An unacceptably high false-resistance rate and a poor reproducibility record make the disk elution procedure unsatisfactory for routine <b>testing</b> <b>of</b> this <b>drug</b> or combination <b>of</b> <b>drugs...</b>|$|R
25|$|Linstead {{was on the}} Joint Subcommittee of the English and Scottish Standing Medical Advisory Committee {{that was}} set up {{following}} the thalidomide disaster, and was in favour of legislation governing the <b>testing</b> <b>of</b> new <b>drugs.</b>|$|R
30|$|In conclusion, {{development}} of biomarkers assessing the turnover of minor collagens may provide novel and translational diagnostic tools for investigating the effect <b>of</b> known <b>drug</b> targets on cartilage in preclinical or clinical settings, thereby providing proof <b>of</b> principle for <b>test</b> <b>of</b> those <b>drugs</b> in OA clinical trials.|$|R
5000|$|In the 1940s, the Central Intelligence Agency (CIA) began {{experimenting with}} {{different}} techniques for interrogation—one used sedatives to induce a trance state while another used two different drugs, {{such as an}} upper and a downer. Director Roscoe H. Hillenkoetter authorized funds for a secret mind control project code named Project BLUEBIRD, which became Project ARTICHOKE in 1951. Project MKULTRA, a covert research operation run by the CIA's Scientific Intelligence Division, began experimenting with human behavioral engineering in 1953. LSD became illegal in 1966. CIA <b>testing</b> <b>of</b> <b>drugs</b> in various forms continued until 1967. [...] LSD was listed as a Schedule I drug in 1970.|$|E
50|$|Project CHATTER was a United States Navy program {{beginning}} {{in the fall of}} 1947 focusing on the identification and <b>testing</b> <b>of</b> <b>drugs</b> in interrogations and the recruitment of agents. Their search included laboratory experiments on both animal and human subjects. The program operated under the direction of Charles Savage of the Naval Medical Research Institute, Bethesda, Maryland, from 1947 to 1953. The project was geared to identifying agents both synthetic and natural that were effective during interrogation. The project was centered on, but not restricted to, the use of anabasine (an alkaloid), scopolamine and mescaline. The program ended shortly after the Korean War in 1953, presumably due to limited progress and the success of other projects.|$|E
5000|$|Eighty-two {{percent of}} primate {{procedures}} in the UK in 2006 were in applied studies, which the Home Office defines as research conducted {{for the purpose of}} developing or testing commercial products. Toxicology testing is the largest use, which includes legislatively required <b>testing</b> <b>of</b> <b>drugs.</b> The second largest category of research using primates is [...] "protection of man, animals, or environment", accounting for 8.9% of all procedures in 2006. The third largest category is [...] "fundamental biological research,", accounting for 4.9% of all UK primate procedures in 2006. This includes neuroscientific study of the visual system, cognition, and diseases such as Parkinson's, involving techniques such as inserting electrodes to record from or stimulate the brain, and temporary or permanent inactivation of areas of tissue.|$|E
50|$|Several {{combinations}} <b>of</b> <b>drugs</b> {{have been}} <b>tested.</b> Some <b>of</b> them are couples <b>of</b> approved <b>drugs.</b> Other <b>tests</b> try one approved drug with one experimental substance. Finally, {{at some point}} there could appear some trials <b>testing</b> couples <b>of</b> non-approved <b>drugs.</b>|$|R
50|$|The current {{research}} has shown progress in the <b>testing</b> <b>of</b> <b>drug</b> resistance. A {{recent study found that}} a research technique known as direct nitrate reductase assay (D-NRA) showed efficient accuracy for the rapid and simultaneous detection of resistance to isoniazid (INH), rifampicin (RIF), kanamycin (KAN) and ofloxacin (OFL). D-NRA results were obtained in 16.9 days, comparably less than other drug susceptibility testing. At the same time the study mentioned how D-NRA is a low-cost technology, easy to set up in clinical laboratories and suitable to be used for DST of M. tuberculosis in all smear-positive samples.|$|R
30|$|In the {{continuing}} absence <b>of</b> widespread <b>testing</b> <b>of</b> veterinary <b>drugs,</b> the quality <b>of</b> these generic products remains frustratingly uncertain. The consensus, however, was that such generics were {{by no means}} universally poor, but rather uneven and unpredictable in quality.|$|R
5000|$|Fazey {{drafted the}} UN Declaration on the Guiding Principles of Demand Reduction that was {{approved}} by a United Nations General Assembly Special Session in 1998. The Declaration was carefully worded to allow harm reduction measures, containing provisions such as [...] "Demand reduction shall: (i) Aim at preventing {{the use of drugs}} and at reducing the adverse consequences of drug abuse" [...] and [...] "Demand reduction programmes should cover all areas of prevention from discouraging initial use to reducing the negative health and social consequences of drug abuse." [...] According to Fazey, this could be interpreted to permit [...] "exchange and distribution of needles and syringes, the prescription of heroin, injecting rooms and even on the spot <b>testing</b> <b>of</b> <b>drugs</b> like ecstasy." ...|$|E
50|$|The use of {{non-human}} primates in the EU {{is regulated}} under the Directive 2010/63/EU. The directive took effect on January 1, 2013. The directive permits {{the use of}} non-human primates if no other alternative methods are available. Testing on non-human primates is permitted for basic and applied research, quality and safety <b>testing</b> <b>of</b> <b>drugs,</b> food and other products and research aimed on {{the preservation of the}} species. The use of great apes is generally not permitted, unless it is believed that the actions are essential to preserve the species or in relation to an unexpected outbreak of a life-threatening or debilitating clinical condition in human beings. The directive stresses the use of the 3R principle (replacement, refinement, reduction) and animal welfare when conducting animal testing on non-human primates.|$|E
50|$|An even {{broader range}} of {{biomedical}} technologies is pursued by scientists supported though the NIBIB Extramural Research Program. These span the development of tissue chips for laboratory <b>testing</b> <b>of</b> <b>drugs,</b> biomedical imaging techniques for better diagnosis and treatment, targeted delivery and controlled release of therapeutic agents to specific sites within the body, rehabilitation engineering technologies to help people with disabilities lead more full and productive lives, point-of-care technologies for rapid {{diagnosis and treatment of}} infectious and non-infectious diseases, and more. The Institute provides informational fact sheets that explain biomedical and bioengineering research topics, such as Computational Modeling, Drug Delivery Systems, Image-Guided Robotic Interventions, Magnetic Resonance Imaging (MRI), Mammography, Rehabilitation Engineering, and Tissue Engineering and Regenerative Medicine. The Institute provides training opportunities to introduce and help propel the careers of talented researchers into the biomedical imaging and bioengineering fields.|$|E
5000|$|From its inception, the US Government {{has charged}} the FDA {{with a mission}} <b>of</b> {{overseeing}} <b>testing</b> <b>of</b> new <b>drugs.</b> Challenges to this core definition, as in the Abigail Alliance court case, would likely require broad changes to the FDA's operating mandate.|$|R
40|$|When {{antibiotic}} combinations {{are used}} to provide a broader spectrum of antimicrobial activity or {{in an attempt to}} prevent the emergence of resistant organisms, it is rarely necessary or practical to perform <b>tests</b> <b>of</b> <b>drug</b> interactions in vitro. In vitro <b>testing</b> <b>of</b> combinations may be useful when combinations are used in an attempt to attain synergistic interactions. In some cases, screening methods can be used as substitutes for formal synergy testing. This paper examines the mechanisms of antibiotic interaction leading to synergism or antagonism, surveys attempts to correlate in vitro observations with efficacy in animal models, and reviews clinical data providing evidence for or against a useful role of synergistic antibiotic interactions in the treatment of human infections...|$|R
40|$|This paper proposes {{publicly}} funding {{prescription drug}} trials {{as an alternative}} to the present system wherein pharmaceutical companies often finance and conduct <b>tests</b> <b>of</b> their <b>drugs</b> themselves. The report posits that in addition to substantial savings for the government, independent companies working under long-term federal contracts would result in full and accurate disclosure of the results <b>of</b> <b>drug</b> <b>testing.</b> presciption drugs, drug testing, drug trials...|$|R
